Echo IQ Limited (ASX:EIQ), an AI and medical technology company based in Sydney, Australia, has disclosed that the US Food and Drug Administration has completed its supervisory review of the company's appeal against the "not substantially equivalent" (NSE) determination for EchoSolv HF and has upheld that determination.
Key Points
- The FDA has completed its supervisory review of Echo IQ's appeal of the NSE determination for EchoSolv HF and upheld that determination.
- The company is evaluating its options with US regulatory and legal advisors, including engaging with the FDA on the path forward, a new 510(k) submission, and further review available under FDA procedures.
- Echo IQ has been working with US regulatory advisors, key opinion leaders, and clinical study partners to prepare for a pre-submission meeting and a potential new 510(k) submission.
- The decision does not affect EchoSolv AS, which remains FDA-cleared and commercially available in the US.
FDA Supervisory Review Outcome for EchoSolv HF
The FDA completed its supervisory review of Echo IQ's appeal of the NSE determination for EchoSolv HF and upheld that determination, according to the company's filing dated 19 November 2026. The company stated it is evaluating its options with its US regulatory and legal advisors. Those options include engaging with the FDA on the path forward, submitting a new 510(k) application, and pursuing further review available under FDA procedures. The company had previously identified a new 510(k) submission as a potential outcome of the review process, as referenced in a prior filing dated 17 September 2026.
Preparation for Pre-Submission Meeting and New 510(k)
In parallel with its ongoing engagement with the FDA, Echo IQ disclosed that it has been working extensively with its US regulatory advisors, key opinion leaders, and clinical study partners over recent weeks to prepare for a pre-submission meeting and a potential new 510(k) submission. The filing states that a potential pathway forward was detailed in the company's most recent correspondence with the FDA. Through ongoing engagement with the regulator, Echo IQ will seek to confirm with the FDA the analysis and clinical evidence required to address the matters raised in the FDA's determination, as well as the most appropriate regulatory pathway.
EchoSolv AS Unaffected by Determination
Echo IQ confirmed in the filing that the FDA's decision regarding EchoSolv HF does not affect EchoSolv AS, which remains FDA-cleared and commercially available in the United States. The company is based in Sydney, Australia, and uses AI-driven technology and proprietary software to improve decision making in cardiology. Echo IQ stated it will keep the market informed in accordance with its continuous disclosure obligations. The filing was authorised for release by the Board of Directors of Echo IQ Limited.



Please wait processing your request...